Skip to main content
Premium Trial:

Request an Annual Quote

Centogene: Berndt Modig

Berndt Modig has resigned from Centogene's supervisory board, effective Aug. 15. In a document filed with the US Securities and Exchange Commission, the company said his resignation did not result from any disagreement with Centogene. Modig had announced in November his intention to resign from the firm's supervisory board. Modig is the cofounder and CEO of Pharvaris, a developer of new oral alternatives for people with hereditary angioedema, according to his LinkedIn profile.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.